恩瑞格去哪购买呢？

The U.S. Food and Drug Administration (FDA) approved a new indication on January 23, 2019, for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT). NTDT is a mild form of thalassemia that does not require frequent blood transfusions. But over time, NTDT patients are at risk for iron overload, which can lead to fatal organ damage. The FDA also approved the marketing of FerriScan as an imaging companion diagnostic reagent from Enrig. The FDA has previously approved FerriScan for the detection of liver iron concentration (LIC), but its use in Enrig clinical studies is to screen patients for clinical treatment and manage treatment. Its use is limited to imaging and diagnostic reagents necessary for the safe and effective application of Enrig.

An estimated 1,000 people in the United States have thalassemia, according to the National Heart, Lung, and Blood Institute. Thalassemia causes the body to produce fewer healthy red blood cells and hemoglobin, which carries oxygen to various parts of the body and transports carbon dioxide from various parts of the body back to the lungs, where it is then exhaled. Some patients with thalassemia require frequent blood transfusions to keep their hemoglobin at an acceptable level. Iron overload is a common phenomenon in these patients. Enrig was previously approved for the treatment of iron overload due to transfusion in patients 2 years of age and older, and this approval allows Enrig to be used in patients with NTDT iron overload. Enrig should be used in patients with NTDT who have at least 5 mg of iron per 1 g of desiccated liver tissue. Enrig's new indication was approved by the FDA through the accelerated approval process, which allows patients to have early access to this promising new drug to treat serious or life-threatening diseases, while the company conducts additional studies to ensure Enrig's clinical effectiveness.

Enriga is marketed by Novartis and has been approved for marketing in China. Domestic patients can obtain Enriga at large hospitals in my country with a prescription, or through professional domestic overseas medical service institutions in India, which is highly cost-effective.